Vivus (VVUS) Surges as Qsymia Prescriptions Rise 46%
Get Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Vivus, Inc. (NASDAQ: VVUS) is stronger early Monday following positive script data.
Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
Shares of Vivus last traded at $12.55, up 9.3 percent.
Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
Shares of Vivus last traded at $12.55, up 9.3 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck's (MRK) Sotatercept Approved by FDA for High Blood Pressure
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!